5.040USD-4.64%Mkt Cap: 4.79M USDP/E: —Last update: 2026-06-03
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for …
Industry Peers
Biotechnology108.72BUSDP/E 25.5
97.22BDKKP/E 18.7
64.89BUSDP/E 15.1
49.40BEURP/E 32.3
45.32BEURP/E 37.6
39.06BUSDP/E 73.5
33.16BUSD—
31.96BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap4.79M USD
Enterprise Value129.78M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.66M USD
Revenue/Share—
Last Price5.040 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees12
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.57
PEG—
EV/EBITDA-6.79
EV/Revenue—
P/S—
P/B0.46
EPS (TTM)-3.71
EPS (Forward)-0.60
52W Range
3.8507% of range20.99
52W High20.99 USD
52W Low3.850 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.82%
ROA-21.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.52M USD
CapEx (TTM)6.66K USD
FCF Margin—
FCF Yield-282.58%
Net Debt-17.81M USD
Net Debt/EBITDA0.93
Balance Sheet
Debt/Equity0.00
Current Ratio6.29
Quick Ratio5.37
Book Value/Sh11.27 USD
Cash/Share19.43 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:28
Split DateMay 15, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.950.30K
Float835.39K
Insiders9.22%
Institutions8.62%
Short Interest
Short Ratio6.3d
Short % Float3.90%
Short % Out.3.90%
Shares Short35.76K
Short (prev mo.)49.98K
Technical
SMA 507.920 (-36.4%)
SMA 2009.522 (-47.1%)
Beta1.40
S&P 52W Chg27.70%
Avg Vol (30d)86.77K
Avg Vol (10d)14.48K
Technical Indicators
RSI (14)20.2
MACD-0.7600
MACD Signal-0.7115
MACD Hist.-0.0485
BB Upper7.877 USD
BB Middle6.224 USD
BB Lower4.571 USD
BB Width53.13%
ATR (14)0.6376 USD
Vol Ratio (20d)196.63x